PTC Therapeutics (PTCT) calls active on FDA approval of Sarepta's (SRPT) eteplirsen
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
PTC Therapeutics (NASDAQ: PTCT) whose Translarna drug seeks to treat nonsense mutation Duchenne muscular dystrophy is recently up 15%, after the FDA granted accelerated approval to Sarepta's (SRPT) eteplirsen, the company's treatment of Duchenne muscular dystrophy. PTCT October 11 and 12 calls are active on total call volume of 805 contracts (134 puts).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Energy Select Sector SPDR ETF (XLE) volatility low as WTI oil near $47
- Volatility and Volume movement
- Stocks with call strike movement; TWTR AA
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!